HOME >> MEDICINE >> NEWS
Spinifex secures $3.25m investment to develop pain therapy

A pain drug development company spun out of The University of Queensland has received a $3.25 million investment commitment to develop its innovative new pain therapy.

Spinifex Pharmaceuticals, an emerging biotechnology company specialising in the development of therapeutics for the treatment of neuropathic pain, has attracted investment from a syndicate including Symbiosis Group Limited, Melbourne-based GBS Venture Partners Limited and Uniseed.

Spinifex Pharmaceutical Managing Director, Dr Michael Thurn said he was delighted by the investment commitment which will help to accelerate their drug development program.

"We've several promising small molecules currently under evaluation and we plan to be in a position to start a formal toxicology program on one of those molecules in 2006," said Dr Thurn.

"The two main causes of neuropathic pain are through diabetes, affecting an estimated 45 per cent of diabetics, and through complications arising from infection with herpes zoster [shingles], known as post-herpetic neuralgia.

"We see a significant world-wide market for our pain therapy, and this investment will progress our efforts in delivering a novel solution."

Spinifex's core technology relates to the discovery (made by University of Queensland researchers led by Professor Maree Smith) of a novel pathway for the treatment of neuropathic pain. Professor Smith's group successfully validated this pathway using small molecules in well-defined animal models of neuropathic pain.

Managing Director of investment company Symbiosis, Dr Mark Harvey, said Spinifex was an attractive investment, led by a strong team with extensive experience in the international and local biotechnology industry

He said the neuropathic pain market targeted by Spinifex's technology was currently valued at US$3 billion.

"With a solid intellectual property position and several 'drug-like' molecules already in hand we expe
'"/>

Contact: Dr Michael Thurn
61-7-3842-3153
Research Australia
26-Jul-2005


Page: 1 2

Related medicine news :

1. University of Rochester spin-off secures $2 million in funding
2. Medical College of Wisconsin secures key contract from US HRSA
3. Molecular Profiling Institute secures $7.5 million in Series B funding
4. Menzies secures $1.8m in funding for the NT
5. ASU secures $3.9 million to study spinal cord injuries and neurological disorders
6. Damon Runyon renews its $2.25 million investment to support young clinical cancer investigators
7. New PBS investment as PBS slows
8. Industry welcomes massive Victorian investment in medical research
9. European Science Foundation warns nanomedicine benefits will be lost without major investment
10. Medicares investment in quality improvement may not be paying off
11. Baby DVDs, videos may hinder, not help, infants language development

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Spinifex secures investment develop pain therapy

(Date:8/5/2015)... ... , ... The June 6 opening of Chicago’s new elevated trail, the 606, has been getting ... a group of walkers at Sedgebrook senior living community in Lincolnshire. Known as the ... preserves and twice per month to more distant places. When they read about the ...
(Date:8/5/2015)... ... 05, 2015 , ... What language does a body speak? "Body Language ... idioms and other expressions that contain the name of a body part. , The ... about 2,000 such idioms, words, and expressions, for example, “back against the wall,” “brainstorming,” ...
(Date:8/5/2015)... ... August 05, 2015 , ... ... filed in the testosterone multidistrict litigation known as Testosterone Replacement Therapy Products Liability ... Northern District of Illinois. The Motion to Dismiss was filed by the defendants, ...
(Date:8/5/2015)... ... ... Wildflower Seed & Tool Company ” was featured on NewsWatch as part of its ... impact in their industry. Susan Bridges, a reporter for NewsWatch and a business expert, ... designed for women. , With overweight gardening tools that seem like they’re designed for ...
(Date:8/5/2015)... ... ... Available in select spas and at http://www.lespausa.com , Phytomer ... oils. A perfect complement to Phytomer’s top selling product, ROSÉE VISAGE Cleansing Toning ... soothing properties. Formulated as a light and comfortable dry oil, it quickly penetrates the ...
Breaking Medicine News(10 mins):Health News:Sedgebrook Trailblazers Tread New Ground on Chicago’s New 606 Path 2Health News:Sedgebrook Trailblazers Tread New Ground on Chicago’s New 606 Path 3Health News:Harvard Medical Professor Dr. Per-Olof Hasselgren Pens Unique Book Using Body Part Idioms 2Health News:Testosterone Lawsuit News: Defendants Push Back Against RICO Claim 2Health News:Testosterone Lawsuit News: Defendants Push Back Against RICO Claim 3Health News:Testosterone Lawsuit News: Defendants Push Back Against RICO Claim 4Health News:Wildflower Seed & Tool Company Design Gardening Tools Specifically for Women 2Health News:Phytomer launches ROSÉE SOIN Radiance Replenishing Oil 2Health News:Phytomer launches ROSÉE SOIN Radiance Replenishing Oil 3Health News:Phytomer launches ROSÉE SOIN Radiance Replenishing Oil 4
(Date:8/4/2015)... SEATTLE , Aug. 4, 2015  Dr. ... Institute states the potential FDA approval of flibanserin, ... sets women and the treatment of decreased female ... women has many root causes and addressing libido ... is dangerous. ...
(Date:8/4/2015)... Pharmaceuticals, Inc. (Nasdaq: ISIS ) today reported net ... three and six months ended June 30, 2015, respectively, ... $43.4 million for the same periods in 2014. Isis, ... more than $90 million of revenue Isis earned in ... Bayer to license  ISIS-FXI Rx .  Isis increased its ...
(Date:8/4/2015)... 2015  Intec Pharma Ltd. (the "Company") (NASDAQ: ... developing drugs based on its proprietary Accordion Pill platform ... offering in the United States ... to the public of $6.00 per ordinary share, before ... are being offered by the Company.  In addition, the ...
Breaking Medicine Technology:Potential FDA Approval of "Pink Viagra" Sends Wrong Message 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 3Potential FDA Approval of "Pink Viagra" Sends Wrong Message 4Potential FDA Approval of "Pink Viagra" Sends Wrong Message 5Isis Reports Financial Results And Highlights For Second Quarter 2015 2Isis Reports Financial Results And Highlights For Second Quarter 2015 3Isis Reports Financial Results And Highlights For Second Quarter 2015 4Isis Reports Financial Results And Highlights For Second Quarter 2015 5Isis Reports Financial Results And Highlights For Second Quarter 2015 6Isis Reports Financial Results And Highlights For Second Quarter 2015 7Isis Reports Financial Results And Highlights For Second Quarter 2015 8Isis Reports Financial Results And Highlights For Second Quarter 2015 9Isis Reports Financial Results And Highlights For Second Quarter 2015 10Isis Reports Financial Results And Highlights For Second Quarter 2015 11Isis Reports Financial Results And Highlights For Second Quarter 2015 12Isis Reports Financial Results And Highlights For Second Quarter 2015 13Isis Reports Financial Results And Highlights For Second Quarter 2015 14Isis Reports Financial Results And Highlights For Second Quarter 2015 15Isis Reports Financial Results And Highlights For Second Quarter 2015 16Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3
Cached News: